Skip to content Skip to footer
Subscribe Now
Top Performing Drug – Dupixent (April Edition)
INSIGHTS+

Top Performing Drug – Dupixent (April Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc. PharmaShots…
April 26, 2023

Read more

Top Performing Drugs: Proceeding the Series
INSIGHTS+

Top Performing Drugs: Proceeding the Series

Shots: Subsequent to our last year’s series titled “Top Performing Drugs of 2021”, PharmaShots presents a list of 12 high revenue-generating drugs With the ongoing pandemic playing an instrumental role in reshaping the life science industry now and then, it becomes increasingly onerous for the pharmaceutical industry to keep up with the growing global demands…
April 25, 2023

Read more

VIEWPOINTS_Bettina Cockroft_2023
VIEWPOINTS

Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease Treatment

Shots: Bettina gave the details of the study design and shared the preliminary results from the P-I/II STAAR clinical study evaluating ST-920. The data were presented in an oral presentation at the 29th Congress of the European Society of Gene & Cell Therapy 2022  She also talked about enzyme replacement therapy (ERT) which is currently used for the…
April 24, 2023

Read more

VIEWPOINTS_Paul K Owens_2023
VIEWPOINTS

Paul K Owens, VP of Global Brand Development, Insulins & Glucagon at Eli Lilly & Company Shares Insights from the US FDA Approval of Lyumjev

Shots: Paul talked about the approval of the Lyumjev Injection for the improvement of glycemic control in children and adolescents with diabetes. He also shared various details about Lyumjev Paul further discussed the study design and the key findings from the registrational PRONTO-Peds study The interview also talks about Lilly’s Diabetes Solution Center which helps eligible…
April 20, 2023

Read more

VIEWPOINTS_James Graham_2023
VIEWPOINTS

James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical Programs

Shots: James gave an overview of the timeline of Recce Pharmaceuticals' clinical programs with several significant data read-outs in 2022 and 2023 He emphasized the study design and results from the different infectious disease clinical and preclinical programs in its product portfolio The interview highlights how the development and commercialization of New Classes of Synthetic Anti-Infectives…
April 18, 2023

Read more

VIEWPOINTS_Daniel Quirk_2023
VIEWPOINTS

Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu

Shots: Daniel started the discussion by speaking about the epidemiology of plaque and briefed about SOTYKTU approved for the treatment of moderate-to-severe Plaque Psoriasis He also elaborated on the results from the P-III registrational studies POETYK PSO-1 and POETYK PSO-2 The interview also talks about how BMS is advancing its product portfolio to deliver innovative…
April 17, 2023

Read more

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)
INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots: With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
April 13, 2023

Read more

Disease of the Month: Hemophilia
INSIGHTS+

Disease of the Month: Hemophilia

Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures To continue the series for disease of the month, PharmaShots brings this month a summary…
April 11, 2023

Read more

Exclusive_Anne Arnold_2023
EXCLUSIVE

Anne Arnold, Senior Director, Education & Training at Smile Train Shares Insights on New VR Platform for Pediatric Surgery

Shots:  Anne started by talking about the launch of the first-ever cleft surgery virtual reality platform in collaboration with Biodigital, which simulates surgery on cleft lip and palate, a birth condition  Anne explained how the VSS VR Extension technology enables surgeons worldwide to collaborate in virtual operating rooms, ensuring safer surgery and better outcomes for…
April 11, 2023

Read more

Load more